Anti-MRSA agent 13 (Compound 9b) is an effective antimicrobial against methicillin-resistant Staphylococcus aureus (MRSA) with a minimal inhibitory concentration (MIC) of 0.5–2 μg/mL for clinically isolated strains. It exhibits excellent biocompatibility, stable plasma tolerance, and a low propensity for resistance. Anti-MRSA agent 13 disrupts the cell wall and membrane, reduces metabolic activity, induces oxidative damage, and impairs DNA function, leading to MRSA death through a multi-target synergistic mechanism.